

# PETER KNUDSEN

Partner  
pknudsen@patentgc.com

Peter Knudsen joined Patent GC in 2021, bringing a combination of business acumen and patent strategy to his technology and academic clients.

Peter's practice has included developing patent platforms for new drugs, including proteins; new biologics, including nanoparticle formulations for delivery of proteins and nucleic acids; and manufacture of nanoparticles. Peter has also developed patent platforms for genetically modified organisms, including plants and mammals, and plants produced by conventional hybridization and/or natural selection. Peter has represented large pharmaceutical companies and start-up companies, managing the development of IP portfolios, including therapies based on traditional drugs as well as therapies based on biologics. In addition, Peter has represented several academic groups in patent procurement projects including cell-based immunotherapies; diagnostic systems based on miRNA and gene sequencing, including diagnostic and prognostic models for cancer; drugs and methods for modulating energy metabolism; and viral vectors for novel gene therapies, including knockdown of expression and immunomodulation.

## EDUCATION

St. John's University, J.D.  
University of California, Berkley, Ph.D.  
University of California, Berkley, B.S.

## SECTORS AND SERVICES

[Intellectual Property](#)  
[Healthcare](#)

## CREDENTIALS

### Bar Admissions

Washington  
New York  
U.S. Patent & Trademark Office  
U.S. Supreme Court

Before joining Patent GC, Peter was a partner for nearly 20 years at Baker Hostetler (and its predecessor firm) in Seattle, where he was responsible for developing and managing patent portfolios for biotechnology clients. Peter regularly conducted clearance and due diligence analysis for advisory opinions and IP strategy, and advised clients regarding IP ownership issues, including those involving contractual relations with business partners, research collaborators, CROs, and government contracts. Prior to Baker Hostetler, Peter was Vice President, Intellectual Property for Nanotech Pharmaceutical and MDRNA, a NASDAQ-listed biotechnology company.

Before becoming a lawyer, Peter was on the faculty at Columbia University and at Harvard University, where he managed and directed research in molecular immunology and virology.

Peter received his law degree from St. John's University, and his undergraduate degree in psychology and his Ph D in biophysics from UC Berkeley.

Peter is admitted to practice in Washington State and New York State, and before the United States Patent and Trademark Office, the Federal Circuit Court of Appeals and the United States Supreme Court.